Alberto J Montero

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. pmc Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
    Claudia Marcela Diaz
    Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
    J Transl Med 11:62. 2013
  2. pmc Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review
    Roberto Ochoa
    Sylvester Comprehensive Cancer Center, University of Miami, Leonard M, Miller School of Medicine, 1475 N, W, 12th Avenue Suite 3410, Miami, FL 33136, USA
    J Med Case Rep 6:413. 2012
  3. doi The economic burden of metastatic breast cancer: a U.S. managed care perspective
    Alberto J Montero
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 N W 12th Avenue, Miami, FL 33136, USA
    Breast Cancer Res Treat 134:815-22. 2012
  4. doi Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature
    Alberto J Montero
    Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136 1002, USA
    Am J Ther 18:e12-8. 2011
  5. pmc Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
    A J Montero
    Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Suite 3510 D8 4, Miami, FL 33136, USA
    Breast Cancer Res Treat 132:215-23. 2012
  6. doi Cellular redox pathways as a therapeutic target in the treatment of cancer
    Alberto J Montero
    Department of Internal Medicine, University of Miami Sylvester Comprehensive Cancer Center, FL, USA
    Drugs 71:1385-96. 2011
  7. pmc Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
    Alberto J Montero
    UM Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
    Curr Oncol Rep 14:1-11. 2012
  8. pmc Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)
    Mohamed L Salem
    Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
    J Immunol 182:2030-40. 2009
  9. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
  10. pmc The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress
    C Marcela Diaz-Montero
    Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Free Radic Biol Med 52:1560-8. 2012

Collaborators

Detail Information

Publications27

  1. pmc Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
    Claudia Marcela Diaz
    Medical University of South Carolina, Hollings Cancer Center, Charleston, USA
    J Transl Med 11:62. 2013
    ..We report the results of 2 multicenter phase 1 trials involving adult cancer patients (n=33) with stage II-IV disease...
  2. pmc Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review
    Roberto Ochoa
    Sylvester Comprehensive Cancer Center, University of Miami, Leonard M, Miller School of Medicine, 1475 N, W, 12th Avenue Suite 3410, Miami, FL 33136, USA
    J Med Case Rep 6:413. 2012
    ..abstract:..
  3. doi The economic burden of metastatic breast cancer: a U.S. managed care perspective
    Alberto J Montero
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 N W 12th Avenue, Miami, FL 33136, USA
    Breast Cancer Res Treat 134:815-22. 2012
    ..Assuming average PPPM costs of $9,788 and an average life expectancy of 2.2 years, the total average expenditure to treat mBC would be ~$250,000 per patient...
  4. doi Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature
    Alberto J Montero
    Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136 1002, USA
    Am J Ther 18:e12-8. 2011
    ....
  5. pmc Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
    A J Montero
    Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Avenue, Suite 3510 D8 4, Miami, FL 33136, USA
    Breast Cancer Res Treat 132:215-23. 2012
    ..Patients with lower levels of circulating MDSCs at baseline and on the last cycle of chemotherapy had significantly higher probability of a pCR (P = 0.02). Further evaluation of NOV-002 in a randomized study is warranted...
  6. doi Cellular redox pathways as a therapeutic target in the treatment of cancer
    Alberto J Montero
    Department of Internal Medicine, University of Miami Sylvester Comprehensive Cancer Center, FL, USA
    Drugs 71:1385-96. 2011
    ..In this article we review anticancer drugs currently in development that target cellular redox activity to treat cancer...
  7. pmc Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
    Alberto J Montero
    UM Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
    Curr Oncol Rep 14:1-11. 2012
    ..This review looks at all available phase 3 data with bevacizumab in the MBC setting to determine whether the data support this decision by the FDA, and discusses the future of bevacizumab in breast cancer...
  8. pmc Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)
    Mohamed L Salem
    Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
    J Immunol 182:2030-40. 2009
    ..In conclusion, our data show that CTX treatment induces, during the restoration phase, expansion of immature DCs, which are functional and can be exploited in vivo to foster more effective antitumor adoptive immunotherapy strategies...
  9. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
    ..This information must be incorporated into the design of future trials exploring immune-based therapeutic strategies. Pharmacologic modulation of MDSC should also be tested in future clinical trials...
  10. pmc The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress
    C Marcela Diaz-Montero
    Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Free Radic Biol Med 52:1560-8. 2012
    ....
  11. doi A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Alberto J Montero
    Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
    Breast Cancer Res Treat 132:747-51. 2012
    ..Bevacizumab plus paclitaxel is not cost-effective in treating MBC. Value-based pricing and the development of biomarkers to improve patient selection are needed to better define the role of the drug in this population...
  12. doi Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma
    Ulas Darda Bayraktar
    Division of Hematology Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave St, Miami, FL 3300, USA
    Med Oncol 29:1707-10. 2012
    ..0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting...
  13. doi A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer
    Peter J Hosein
    Department of Medicine, Division of Hematology Oncology, Miller School of Medicine, University of Miami, Miami, FL Department of Oncology, Johns Hopkins Singapore International Medical Center, Singapore, Republic of Singapore
    Am J Clin Oncol 36:151-6. 2013
    ..This study was designed to determine the efficacy of nab-paclitaxel monotherapy in previously treated pancreatic cancer patients...
  14. doi Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review
    Alberto J Montero
    Department of Medicine, Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Leonard M Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA
    Expert Rev Clin Pharmacol 4:329-34. 2011
    ..While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article...
  15. doi Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status
    Joan E Cunningham
    Hollings Cancer Center, Medical University of South Carolina, Charleston, 29425, USA
    Cancer Causes Control 21:399-409. 2010
    ..This approach also may aid in estimating the race-specific incidence rates of triple-negative breast cancer...
  16. pmc Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory
    C Marcela Diaz-Montero
    Department of Medicine, Division of Hematology Oncology, Sylvester Cancer Center, University of Miami, Miami, FL33136, USA
    Am J Cancer Res 1:882-96. 2011
    ....
  17. pmc Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
    Matthew A Beldner
    Division of Medical Oncology Hematology, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA
    BMC Cancer 7:231. 2007
    ....
  18. pmc Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA
    Cancer Immunol Immunother 57:563-72. 2008
    ..Together, our results suggest that in vitro conditioning of naïve CD8+ T cells with IL-12 prior to ACT could significantly enhance their anti-tumor activity...
  19. pmc Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    John Hayslip
    Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
    BMC Cancer 7:221. 2007
    ..The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of bortezomib in combination with celecoxib in patients with advanced solid tumors...
  20. ncbi Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review
    Vinay Gudena
    Department of Hematology Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Biol Ther 7:810-3. 2008
    ..Studies are ongoing and the results are eagerly awaited regarding the responses to these medications and whether they can positively impact on the natural history of this disease...
  21. pmc Treating breast cancer in the 21st century: emerging biological therapies
    Gabriel Tinoco
    1 Department of Medicine, Division of Hospital Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    J Cancer 4:117-32. 2013
    ....
  22. doi Myeloid-derived suppressor cells in cancer patients: a clinical perspective
    Alberto J Montero
    Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
    J Immunother 35:107-15. 2012
    ..Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies...
  23. pmc Gemcitabine and taxanes in metastatic breast cancer: a systematic review
    Vinay Gudena
    Division of Hematology Oncology, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
    Ther Clin Risk Manag 4:1157-64. 2008
    ..This review will discuss data supporting the use of gemcitabine/taxane combinations in the treatment of MBC...
  24. doi Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
    Allyson J Ocean
    Department of Medicine, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 118:5497-506. 2012
    ....
  25. doi Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma
    Relin Yang
    DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, FL 33136, USA
    Arch Surg 145:49-56. 2010
    ..The survival benefit of adjuvant chemotherapy alone or chemoradiotherapy in patients with pancreatic cancer who have undergone surgical resection remains unclear...
  26. ncbi Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma
    Amy Skorupa
    Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Cancer Biol Ther 6:1015-7. 2007
    ..Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment...
  27. ncbi Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer
    Alberto J Montero
    Division of Hematology Oncology, Medical University of South Carolina, Charleston, South Carolina, USA
    Cancer Biol Ther 5:1494-501. 2006
    ..In conclusion, EGFR is hypermethylated and silenced in a subset of solid tumor cell lines and primary tumor specimens, and cotreatment with decitabine and gefitinib has an additive effect only in EGFR methylated breast cancer cell lines...